Abstract:Flaviviruses represent a significant global health threat and relatively few licensed vaccines exist to protect against them. Insect-specific flaviviruses (ISFVs) are incapable of replication in humans and have emerged as a novel and promising tool for flavivirus vaccine development. ISFV-based flavivirus vaccines have shown exceptional safety, immunogenicity, and efficacy, however, a detailed assessment of the correlates of protection and immune responses induced by these vaccines are still needed for vaccine optimization. Here, we explore the mechanisms of protective immunity induced by a previously created pre-clinical Zika virus (ZIKV) vaccine candidate, called Aripo/Zika (ARPV/ZIKV). In brief, immunocompromised IFN-αβR -/- mice passively immunized with ARPV/ZIKV immune sera experienced protection after lethal ZIKV challenge, although this protection was incomplete. ARPV/ZIKV-vaccinated IFN-αβR -/- mice depleted of CD4 + or CD8 + T-cells at the time of ZIKV challenge showed no morbidity or mortality. However, the adoptive transfer of ARPV/ZIKV-primed T-cells into recipient IFN-αβR -/- mice resulted in a two-day median increase in survival time compared to controls. Altogether, these results suggest that ARPV/ZIKV-induced protection is primarily mediated by neutralizing antibodies at the time of challenge and that T-cells may play a comparatively minor but cumulative role in the protection observed. Lastly, ARPV/ZIKV-vaccinated Tcra KO mice, which are deficient in T-cell responses, experienced significant mortality post-challenge. These results suggest that ARPV/ZIKV-induced cell-mediated responses are critical for development of protective immune responses at vaccination. Despite the strong focus on neutralizing antibody responses to novel flavivirus vaccine candidates, these results suggest that cell-mediated responses induced by ISFV-based vaccines remain important to overall protective responses. Conventional vaccine development platforms may involve trade-offs between vaccine safety and immunogenicity, but insect-specific viruses have recently emerged as a promising platform to overcome this challenge. We previously developed a preclinical Zika virus (ZIKV) vaccine candidate named Aripo/Zika virus (ARPV/ZIKV) based on a novel ISFV called Aripo virus (ARPV). Our previous studies demonstrated the high degree of safety as well as the single dose efficacy of ARPV/ZIKV. Here, we begin to elucidate the mechanisms of protection for this vaccine candidate. We demonstrate the dominant role of neutralizing antibodies in providing protection post-challenge, but also the importance of ARPV/ZIKV-induced T-cell responses in the priming phase of immunity. Overall, even high efficacy ISFV-based vaccine candidates such as ARPV/ZIKV may benefit from adjuvants or optimization strategies to increase protective T-cell responses. However, ARPV/ZIKV remains a promising ZIKV vaccine candidate, and contributes to the rapidly growing body of work that supports the potential of ISFVs as a new tool for protecting the health of the millions of people currently at risk of infection.

The Zika virus NS1 protein as a vaccine target

A Zika Vaccine Targeting NS1 Protein Protects Immunocompetent Adult Mice in a Lethal Challenge Model

Vesicular Stomatitis Virus and DNA Vaccines Expressing Zika Virus Nonstructural Protein 1 Induce Substantial but Not Sterilizing Protection against Zika Virus Infection

Novel Non-Segmented Negative-Sense Rna Virus-Based Vaccine Platforms For Zika Virus

Antibodies targeting epitopes on the cell-surface form of NS1 protect against Zika virus infection during pregnancy

Exploring the immunogenicity of an insect-specific virus vectored Zika vaccine candidate

Defeat Dengue and Zika Viruses With a One-Two Punch of Vaccine and Vector Blockade

Humoral and T-cell-mediated responses to an insect-specific flavivirus-based Zika virus vaccine candidate

A broadly protective antibody that targets the flavivirus NS1 protein

A safe replication-defective Zika virus vaccine protects mice from viral infection and vertical transmission

Monoclonal Antibodies against Zika Virus NS1 Protein Confer Protection via Fc γ Receptor-Dependent and -Independent Pathways

Potential Protective Effect of Dengue NS1 Human Monoclonal Antibodies against Dengue and Zika Virus Infections

The NS1 protein of contemporary West African Zika virus potentiates viral replication and reduces innate immune activation

NS1-based DNA vaccination confers mouse protective immunity against ZIKV challenge

Characterization of Two Highly Specific Monoclonal Antibodies Targeting the Glycan Loop of the Zika Virus Envelope Protein

Recent advances in the study of zika virus structure, drug targets, and inhibitors

The NS1 protein of contemporary West African Zika virus is efficient to increase cellular permissiveness to virus replication

A novel vaccine construct against Zika virus fever: insights from epitope-based vaccine discovery through molecular modeling and immunoinformatics approaches

A Recombinant Subunit Based Zika Virus Vaccine Is Efficacious in Non-human Primates

Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection

Zika Virus—A Reemerging Neurotropic Arbovirus Associated with Adverse Pregnancy Outcomes and Neuropathogenesis